Atorvastatin therapy during the Peri-Infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Tang, Xian Liang ^a   Sanganalmath, Santosh K ^a   Sato, Hiroshi ^a   Bi, Qiuli ^a   Hunt, Greg ^a   Vincent, Robert J ^b   Peng, Yong ^a   Shirk, Gregg ^a   Dawn, Buddhadeb ^b   Bolli, Roberto ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYPROLINE; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE ASYNERGY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; MORPHOMETRICS; NONHUMAN; RAT; ANIMAL; APOPTOSIS; DRUG EFFECT; FISCHER 344 RAT; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; METABOLISM; MUSCLE CONTRACTION; PATHOLOGY; PATHOPHYSIOLOGY;

RATTUS;

ANIMALS; APOPTOSIS; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYDROXYPROLINE; MUSCLE CONTRACTION; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PYRROLES; RATS; RATS, INBRED F344; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 80053227771     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025320     Document Type: Article

References (48)

1. Pfeffer MA, Braunwald E, (1990) Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161-1172.
2. Swynghedauw B, (1999) Molecular mechanisms of myocardial remodeling. Physiological reviews 79: 215-262.
3. Covell JW, (1990) Factors influencing diastolic function. Possible role of the extracellular matrix. Circulation 81: III155-158.
4. Wu Y, Tobias AH, Bell K, Barry W, Helmes M, et al. (2004) Cellular and molecular mechanisms of systolic and diastolic dysfunction in an avian model of dilated cardiomyopathy. Journal of molecular and cellular cardiology 37: 111-119.
5. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. The New England journal of medicine 327: 669-677.
6. (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. The New England journal of medicine 325: 293-302.
7. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
8. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. The New England journal of medicine 335: 1001-1009.
9. Libby P, (1995) Molecular bases of the acute coronary syndromes. Circulation 91: 2844-2850.
10. Vaughan CJ, Gotto AM Jr, Basson CT, (2000) The evolving role of statins in the management of atherosclerosis. Journal of the American College of Cardiology 35: 1-10.
11. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV, (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. Journal of the American College of Cardiology 47: 332-337.
12. Laufs U, Wassmann S, Schackmann S, Heeschen C, Bohm M, et al. (2004) Beneficial effects of statins in patients with non-ischemic heart failure. Zeitschrift fur Kardiologie 93: 103-108.
13. Krum H, Ashton E, Reid C, Kalff V, Rogers J, et al. (2007) Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. Journal of cardiac failure 13: 1-7.
14. Schmechel A, Grimm M, El-Armouche A, Hoppner G, Schwoerer AP, et al. (2009) Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Cardiovascular research 82: 100-106.
15. Filusch A, Buss S, Hardt S, Katus HA, Kuecherer HF, et al. (2008) Evaluation cardioprotective effects of atorvastatin in rats by real time myocardial contrast echocardiography. Echocardiography 25: 974-981.
16. Birnbaum Y, Ashitkov T, Uretsky BF, Ballinger S, Motamedi M, (2003) Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy 17: 25-30.
17. Aronow HD, Lincoff AM, Quinn MJ, McRae AT, Gurm HS, et al. (2008) Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction. The American journal of cardiology 102: 1119-1124.
18. Stefanadi E, Tousoulis D, Antoniades C, Katsi V, Bosinakou E, et al. (2009) Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation. International journal of cardiology 133: 266-268.
19. Stein AB, Tiwari S, Thomas P, Hunt G, Levent C, et al. (2007) Effects of anesthesia on echocardiographic assessment of left ventricular structure and function in rats. Basic research in cardiology 102: 28-41.
20. Litwin SE, Katz SE, Morgan JP, Douglas PS, (1994) Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 89: 345-354.
21. Tang XL, Rokosh G, Sanganalmath SK, Yuan F, Sato H, et al. (2010) Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation 121: 293-305.
22. Anversa P, Loud AV, Levicky V, Guideri G, (1985) Left ventricular failure induced by myocardial infarction. II. Tissue morphometry. The American journal of physiology 248: H883-889.
23. Switzer BR, Summer GK, (1971) Improved method for hydroxyproline analysis in tissue hydrolyzates. Analytical biochemistry 39: 487-491.
24. Didenko VV, Boudreaux DJ, Baskin DS, (1999) Substantial background reduction in ligase-based apoptosis detection using newly designed hairpin oligonucleotide probes. BioTechniques 27: 1130-1132.
25. Assayag P, Carre F, Chevalier B, Delcayre C, Mansier P, et al. (1997) Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovascular research 34: 439-444.
26. Rossi MA, (1998) Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. Journal of hypertension 16: 1031-1041.
27. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G, (2001) Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104: 982-985.
28. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, et al. (2002) Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105: 868-873.
29. Node K, Fujita M, Kitakaze M, Hori M, Liao JK, (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108: 839-843.
30. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, et al. (2006) Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. The American journal of cardiology 97: 899-904.
31. Herrmann J, Lerman A, Baumgart D, Volbracht L, Schulz R, et al. (2002) Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 106: 2180-2183.
32. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, et al. (2009) Coronary microembolization: from bedside to bench and back to bedside. Circulation 120: 1822-1836.
33. Weinberg EO, Scherrer-Crosbie M, Picard MH, Nasseri BA, MacGillivray C, et al. (2005) Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. Am J Physiol Heart Circ Physiol 288: H1802-1809.
34. Ye Y, Martinez JD, Perez-Polo RJ, Lin Y, Uretsky BF, et al. (2008) The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 295: H343-351.
35. Iliodromitis EK, Andreadou I, Prokovas E, Zoga A, Farmakis D, et al. (2010) Simvastatin in contrast to postconditioning reduces infarct size in hyperlipidemic rabbits: possible role of oxidative/nitrosative stress attenuation. Basic research in cardiology 105: 193-203.
36. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, et al. (2004) Myocardial protection at a crossroads: the need for translation into clinical therapy. Circulation research 95: 125-134.
37. Trochu JN, Mital S, Zhang X, Xu X, Ochoa M, et al. (2003) Preservation of NO production by statins in the treatment of heart failure. Cardiovascular research 60: 250-258.
38. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, et al. (2002) Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106: 1447-1452.
39. Pliquett RU, Cornish KG, Peuler JD, Zucker IH, (2003) Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 107: 2493-2498.
40. Yao L, Chen GP, Lu X, Zheng LR, Mou Y, et al. (2009) Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats. Basic research in cardiology 104: 258-268.
41. Van Linthout S, Riad A, Dhayat N, Spillmann F, Du J, et al. (2007) Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 50: 1977-1986.
42. Kang L, Ge CJ, Hu SJ, (2007) Beneficial effect of atorvastatin on left ventricular remodeling in spontaneously hypertensive rats. Pharmacology 80: 120-126.
43. Alpert NR, Hamrell BB, Mulieri LA, (1979) Heart muscle mechanics. Annual review of physiology 41: 521-537.
44. Zile MR, Brutsaert DL, (2002) New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105: 1387-1393.
45. Sutton MG, Sharpe N, (2000) Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101: 2981-2988.
46. Weber KT, (1997) Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96: 4065-4082.
47. Oi S, Haneda T, Osaki J, Kashiwagi Y, Nakamura Y, et al. (1999) Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. European journal of pharmacology 376: 139-148.
48. Didenko VV, Tunstead JR, Hornsby PJ, (1998) Biotin-labeled hairpin oligonucleotides: probes to detect double-strand breaks in DNA in apoptotic cells. The American journal of pathology 152: 897-902.